British–Swedish multinational pharmaceutical company AstraZeneca on Thursday forecast higher sales in 2022 after posting a better-than-expected fourth-quarter profit.
But the biotechnology company warned that it expects revenues to decline as sales of its COVID-19 products drop, and that the gross profit margins from those products would be lower than the company average.
